{'52WeekChange': -0.4479472,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Technology Square',
 'address2': '5th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.5,
 'askSize': 900,
 'averageDailyVolume10Day': 290487,
 'averageVolume': 321125,
 'averageVolume10days': 290487,
 'beta': 2.821951,
 'beta3Year': None,
 'bid': 7.5,
 'bidSize': 900,
 'bookValue': 3.178,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.685,
 'dayLow': 7.39,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.985,
 'enterpriseToRevenue': None,
 'enterpriseValue': 170623312,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 8.680285,
 'fiftyTwoWeekHigh': 16.19,
 'fiftyTwoWeekLow': 5.76,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21317204,
 'forwardEps': -2.12,
 'forwardPE': -3.551887,
 'fromCurrency': None,
 'fullTimeEmployees': 70,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.16226,
 'heldPercentInstitutions': 0.75196,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/magentatx.com',
 'longBusinessSummary': 'Magenta Therapeutics, Inc., a clinical-stage '
                        'biotechnology company, develops novel medicines to '
                        'extend the curative power of stem cell transplant, '
                        'gene therapy, genome editing, and cell therapy to '
                        'patients. Thecompany is developing C100, C200, and '
                        'C300 targeted antibody-drug conjugates for transplant '
                        'conditioning; MGTA-145, a novel stem cell '
                        'mobilization product candidate to control stem cell '
                        'mobilization; MGTA-456, an allogeneic stem cell '
                        'therapy to control stem cell growth; E478, a small '
                        'molecule aryl hydrocarbon receptor antagonist for the '
                        'expansion of gene-modified stem cells; and G100, an '
                        'antibody-drug conjugate program to prevent acute '
                        'graft and host diseases. It has a has a research and '
                        'clinical collaboration agreement with AVROBIO, Inc.to '
                        'evaluate targeted antibody-drug conjugate as a '
                        'conditioning regimen for lentiviral gene therapies. '
                        'The company was formerly known as HSCTCo '
                        'Therapeutics, Inc. and changed its name to Magenta '
                        'Therapeutics, Inc. in February 2016. Magenta '
                        'Therapeutics, Inc. was founded in 2015 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Magenta Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 363281856,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_409918376',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -81946000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 242 0170',
 'previousClose': 7.65,
 'priceHint': 2,
 'priceToBook': 2.3694148,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.685,
 'regularMarketDayLow': 7.39,
 'regularMarketOpen': 7.6,
 'regularMarketPreviousClose': 7.65,
 'regularMarketPrice': 7.6,
 'regularMarketVolume': 214257,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 48244600,
 'sharesPercentSharesOut': 0.030199999,
 'sharesShort': 1455232,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 904653,
 'shortName': 'Magenta Therapeutics, Inc.',
 'shortPercentOfFloat': 0.049200002,
 'shortRatio': 3.87,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'MGTA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.128,
 'twoHundredDayAverage': 9.819569,
 'volume': 214257,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.magentatx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}